Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
American chemical industry news
(page 9)
25 February 2026
ViiV Healthcare Unveils Data on Twice-Yearly HIV Treatments
VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.
25 February 2026
Merck Animal Health's NUMELVI: FDA-Approved JAK Inhibitor for Canine Allergic Dermatitis
FDA approves NUMELVI for dogs 6+ months, a JAK inhibitor for allergic dermatitis, offering rapid itch relief and easy dosing. Available spring 2026.
25 February 2026
Merck Presents Phase 3 Trial Results for HIV-1 Treatment DOR/ISL at CROI 2026
DOR/ISL shows non-inferiority and similar safety to BIC/FTC/TAF in HIV-1 treatment-naïve adults and maintains suppression in those switching from other therapies.
25 February 2026
BASF SE Nominates Mark Garrett for Supervisory Board Election 2026
Mark Garrett, former CEO and board member, is nominated to succeed Liming Chen on BASF's Supervisory Board, with the election set for April 2026.
25 February 2026
Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes
The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.
25 February 2026
Clariant Gains EU Approval for Rice Bran Wax in Food-Contact Plastics
EU approval allows rice bran wax additives in PET, PLA, and PVC for food-contact, offering a sustainable alternative to montan wax with lower carbon footprint and supply chain benefits.
How does the American chemical industry perform?
Find out with
chemXplore Alpha
Learn more
25 February 2026
Vopak Announces Record 2025 Results and EUR 1.7 Billion Shareholder Program
Net profit rose 61% to EUR 604M. Operating cash flow hit EUR 823M. EUR 4B investment by 2030 planned. EUR 1.1B in growth projects underway. Energy transition projects worth EUR 200M in progress.
24 February 2026
Honeywell and Verso Energy Partner to Boost eSAF Production
Verso Energy will use Honeywell's eFining technology to produce eSAF, reducing GHG emissions by 88% and meeting EU's 2050 fuel requirements.
24 February 2026
Johnson & Johnson Seeks FDA Approval for IMAAVY® to Treat wAIHA
IMAAVY® targets wAIHA by blocking FcRn, reducing IgG. Phase 2/3 study shows improved hemoglobin and fatigue.
24 February 2026
Iberdrola France Sells Onshore Portfolio to Technique Solaire
The sale includes 118 MW of wind capacity and 639 MW pipeline. It's part of a strategy to focus on core businesses and key markets like the US and UK. Fifth transaction this year.
23 February 2026
LyondellBasell Updates 2030 Sustainability Goals
LYB revises 2030 goals: 32% emissions cut, 800,000 tons recycled polymers. Focus on circular, low-carbon growth, capital discipline, and sustainability.
23 February 2026
Merck Restructures Human Health Division for Enhanced Portfolio Execution
Merck forms Oncology and Specialty units, appoints new leaders, and aims to boost commercial success and pipeline execution.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Sasol reports stable turnover, improved production, and reduced costs. Despite lower earnings, free cash flow rose, supported by strategic initiatives and disciplined management.
23 February 2026
Novo Nordisk: CagriSema Shows 23% Weight Loss in Trial, Misses Primary Endpoint
CagriSema achieved 23% weight loss in 84 weeks but didn't match tirzepatide. Further trials will explore higher doses. Safe profile with mild gastrointestinal effects.
23 February 2026
Sasol Advances Strategic Goals, Meets CMD Targets
Despite a challenging macro environment, Sasol improved production, managed costs, and increased free cash flow, while advancing its Grow and Transform strategy.
21 February 2026
Johnson & Johnson's TREMFYA® Shows Sustained Remission in Ulcerative Colitis Over 3 Years
TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.
20 February 2026
Roche's Giredestrant NDA Accepted by FDA for Advanced Breast Cancer
FDA accepts giredestrant NDA based on phase III data showing reduced disease progression risk in ER-positive breast cancer. Decision expected by December 18, 2026.
19 February 2026
LanzaJet Secures $47M in New Funding, Valued at $650M
Existing investors boost LanzaJet's ATJ technology growth, supporting commercial deployment and securing feedstock supply through a multi-year tolling structure.
19 February 2026
Technip Energies Appoints Jesse Stanley as President of Technologies & Products
Jesse Stanley joins as President, Technologies & Products, enhancing innovation and growth. The Executive Committee's new composition is announced.
19 February 2026
Genentech's Venclexta and Acalabrutinib Combo Approved by FDA for Untreated CLL
FDA approves all-oral, fixed-duration regimen for CLL, reducing treatment time. AMPLIFY study shows 35% lower risk of progression or death compared to chemoimmunotherapy.
19 February 2026
Lilly's Omvoh Maintains Steroid-Free Remission in Crohn's Patients for Three Years
Omvoh shows durable efficacy in Crohn's and UC, with low surgery rates and sustained symptom relief over three years, maintaining steroid-free remission in over 90% of patients.
19 February 2026
Takeda's Phase 3 Study on Pediatric Ulcerative Colitis
Vedolizumab shows promise in treating pediatric ulcerative colitis, achieving 47.3% remission at 54 weeks, with a safety profile consistent with adult use.
19 February 2026
BASF Introduces Circalo for Low Carbon Ethanol Production
Circalo connects farmers and ethanol producers to reduce carbon intensity, aligning with Section 45Z, using xarvio tools for data verification and compliance.
19 February 2026
TechnipFMC Q4 2025 Financial Results
Subsea orders hit $2.3B in Q4; full-year orders $10.1B. Shareholder distributions $188M in Q4, $1B annually. Revenue $2.5B, net income $242.7M, adjusted EBITDA $440.5M, margin 17.5%.
19 February 2026
Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in High-Risk Infants and Children
ENFLONSIA shows consistent safety and efficacy in high-risk infants over two RSV seasons, supporting expanded use for children under 2.
19 February 2026
INEOS Secures €300M French Grant to Decarbonise Lavera Site
The investment cuts CO2 by 331,000 tonnes annually, secures jobs, boosts competitiveness, and supports France's industrial and climate goals through electrification and carbon capture.
19 February 2026
AGC Biologics Gains Anvisa GMP Certification for Seattle Facility
The Seattle site can now supply biopharmaceuticals to Brazil, enhancing AGC's global supply capabilities and expanding regulatory approvals to over 11 countries.
19 February 2026
Asahi Kasei Pharma Partners with MAIA for U.S. Teribone™ Development
MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
18 February 2026
Asahi Kasei Pharma and Alchemedicine: AK1960 enters Phase I for refractory diseases
AK1960, a novel ETA receptor antagonist with a new core structure, shows high ETA selectivity and kidney-disease efficacy in animals and has advanced to Phase I for refractory diseases.
18 February 2026
Johnson & Johnson Invests $1 Billion in Pennsylvania Cell Therapy Facility
The new facility in Montgomery County will boost U.S. manufacturing capacity for cancer, immune-mediated, and neurological disease treatments.
← Previous
Next →
